Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC) Meeting Abstract


Authors: Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; Katabi, N.; Fagin, J.; Pfister, D.; Ho, A. L.
Abstract Title: Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
Meeting Title: ESMO Congress 2024
Journal Title: Annals of Oncology
Volume: 35
Issue: Suppl. 2
Meeting Dates: 2024 Sep 13-17
Meeting Location: Barcelona, Spain
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2024-09-01
Start Page: S1122
Language: English
ACCESSION: WOS:001326612902547
DOI: 10.1016/j.annonc.2024.08.2012
PROVIDER: wos
Notes: Meeting Abstract: 1931P -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James A Fagin
    181 Fagin
  2. Loren Michel
    62 Michel
  3. Eric J Sherman
    341 Sherman
  4. Ravinder K Grewal
    82 Grewal
  5. Nora Katabi
    305 Katabi
  6. David G Pfister
    389 Pfister
  7. Alan Loh Ho
    239 Ho
  8. Lara   Dunn
    141 Dunn
  9. Wanqing Iris Zhi
    48 Zhi
  10. Winston Wong
    29 Wong
  11. Tony K.W. Hung
    32 Hung